Skip to content
Trial Agents

Infraserv GmbH & Co. Hochst KG

Infraserv GmbH & Co. Hochst KG is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

1distinct trials
1recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 1 of 1 trials · Latest update first

A parallel-group treatment, proof-of-concept Phase 2, multicenter, double-blind, randomized two-arm clinical trial to investigate the efficacy and safety of subcutaneous NT 201 injections compared with placebo injections in decreasing pain intensity in male and female participants aged 18 years and older with moderate to severe chronic peripheral neuropathic pain due to postherpetic neuralgia or peripheral nerve injury.

Sponsor Merz Therapeutics GmbH

Start (EU)
Latest update
Estimated end
Not reported
Operational learnings available3 trial-level findings · Read insights
  • Participants were recruited at 26 sites in Bulgaria, France, Germany, Hungary, Poland, and Spain.
  • A protocol amendment specified adjustment of primary and secondary efficacy analyses for painful skin surface area as a potential confounder or modifier because it was proportional to planned injection points.
  • A subsequent protocol amendment reduced the maximum NT 201 dose to 300 U, added pulmonary function tests, adapted the visit schedule, and simplified eCOA data collection.

These findings describe the trial, not the service provider’s performance or responsibility.

Questions about this trial experience

What services are recorded for Infraserv GmbH & Co. Hochst KG?

The 2026-10-09 snapshot links Infraserv GmbH & Co. Hochst KG to 1 distinct CTIS trials. Recorded services include 24 hours emergency unblinding service and hotline. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Infraserv GmbH & Co. Hochst KG?

The most frequently recorded therapeutic areas are Neurology, Pain Medicine. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Infraserv GmbH & Co. Hochst KG conducted?

The linked trials record locations in 6 countries, including Bulgaria, Germany, Spain, France, Hungary. These are trial locations, not confirmed office locations or countries where Infraserv GmbH & Co. Hochst KG delivered services.

What can this page tell me about Infraserv GmbH & Co. Hochst KG's trial experience?

Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Infraserv GmbH & Co. Hochst KG. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Infraserv GmbH & Co. Hochst KG

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.